HER-2 B Cell Peptide Vaccine

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

Trial Details

NCT ID
NCT06414733
Phase
PHASE1
Sponsor
Pravin T.P Kaumaya
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
Locations (sample)
  • Indianpolis, Indiana, United States

Key Eligibility Criteria

  • Inclusion Criteria for Extension and Expansion Cohorts
  • For the extension cohort to be conducted at the IUSCCC (N=12), patients with histologically documented metastatic or unresectable breast or gastroi…
  • For the expansion cohort (N=30), patients with either histologically documented metastatic or unresectable breast cancer (N=15), or histologically …
  • Inclusion Criteria for all Cohorts:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →